• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胶质瘤预后模型的构建与验证:基于错配修复相关基因及其与临床病理特征相关性的分析

Construction and validation of a prognostic model for glioma: an analysis based on mismatch repair-related genes and their correlation with clinicopathological features.

作者信息

Wang Tong, Sun Bohao, Yu Rui, Zhang Jing, Wu Yichen, Wang Delin, Ni Xiaoying, Wang Hao

机构信息

Department of Clinical Laboratory, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.

Department of Pathology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

出版信息

Transl Cancer Res. 2025 May 30;14(5):2690-2706. doi: 10.21037/tcr-24-2045. Epub 2025 May 9.

DOI:10.21037/tcr-24-2045
PMID:40530129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12169988/
Abstract

BACKGROUND

Glioma is a prevalent and aggressive form of brain neoplasm, characterized by a 5-year survival rate of less than 10%. Despite the encouraging outcomes demonstrated by numerous prognostic models for gliomas in preliminary research, these models frequently do not meet anticipated results when subjected to external validation. Our goal is to uncover potential prognostic biomarkers and therapeutic targets by concentrating on mismatch repair-related genes (MRRGs) that are significantly linked to glioma.

METHODS

We employed least absolute shrinkage and selection operator (LASSO) Cox regression to develop a multigene signature based on MRRGs. The functional implications of the gene were evaluated through Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA). We analyzed the correlation between gene expression and immune cell infiltration using single-sample GSEA (ssGSEA). Moreover, we undertook a comprehensive examination of the correlation between expression and several clinical parameters derived from clinical samples obtained from the TCGA database. The parameters assessed encompassed World Health Organization (WHO) grade, isocitrate dehydrogenase (IDH) wild-type status, the status of 1p/19q non-co-deletion, and patient age. Additionally, we executed a thorough prognostic evaluation of EXO1 across various subgroups defined by clinical parameters. Utilizing the "rms" R package, we constructed a nomogram model that amalgamates clinical characteristics and expression levels. Immunohistochemical techniques were utilized to assess expression in sixty glioma cases.

RESULTS

A comparative analysis of the expression of 23 MRRGs between glioma and normal samples revealed that 22 MRRGs were upregulated in glioma tissues. Univariate analysis indicated that 20 of these MRRGs were significantly differentially expressed (P<0.05). The LASSO algorithm reduced this set to seven key genes: , , , , , , and . Kaplan-Meier survival analysis confirmed the association between the aberrant expression of these genes and patient survival outcomes. GO and KEGG enrichment analyses highlighted the role of in crucial biological processes and pathways, including the cell cycle and DNA repair mechanisms. Increased expression of was correlated with higher WHO grades, IDH wild type, 1p/19q non-codel, and poor prognosis. A nomogram that combines EXO1 with clinical parameters has been developed to assist in predicting the overall survival probabilities of patients at 1-year intervals. The calibration chart revealed that effectiveness of the nomogram was accurate (c-index =0.850). Immunohistochemical evaluations showed that expression levels were significantly elevated in 60 glioma tissues compared to adjacent non-tumorous tissues.

CONCLUSIONS

In summary, our results indicate a marked elevation in expression levels within gliomas, which correlates strongly with clinical pathological characteristics and unfavorable prognosis. Moreover, emerges as a promising candidate biomarker and potential therapeutic target for glioma, likely playing a critical role in mediating immune infiltration within this malignancy.

摘要

背景

胶质瘤是一种常见且侵袭性强的脑肿瘤形式,其5年生存率低于10%。尽管众多胶质瘤预后模型在初步研究中显示出令人鼓舞的结果,但这些模型在进行外部验证时常常未达到预期效果。我们的目标是通过关注与胶质瘤显著相关的错配修复相关基因(MRRGs)来发现潜在的预后生物标志物和治疗靶点。

方法

我们采用最小绝对收缩和选择算子(LASSO)Cox回归基于MRRGs开发了一个多基因特征。通过基因本体论(GO)、京都基因与基因组百科全书(KEGG)和基因集富集分析(GSEA)评估该基因的功能意义。我们使用单样本GSEA(ssGSEA)分析基因表达与免疫细胞浸润之间的相关性。此外,我们全面检查了从TCGA数据库获得的临床样本中该基因表达与几个临床参数之间的相关性。评估的参数包括世界卫生组织(WHO)分级、异柠檬酸脱氢酶(IDH)野生型状态、1p/19q非共缺失状态和患者年龄。此外,我们对EXO1在由临床参数定义的各个亚组中进行了全面的预后评估。利用“rms”R包,我们构建了一个整合临床特征和EXO1表达水平的列线图模型。采用免疫组织化学技术评估60例胶质瘤病例中的EXO1表达。

结果

胶质瘤与正常样本之间23个MRRGs表达的比较分析显示,22个MRRGs在胶质瘤组织中上调。单因素分析表明,其中20个MRRGs有显著差异表达(P<0.05)。LASSO算法将这一组基因减少到7个关键基因: 、 、 、 、 、 和 。Kaplan-Meier生存分析证实这些基因的异常表达与患者生存结果之间的关联。GO和KEGG富集分析突出了EXO1在关键生物学过程和途径中的作用,包括细胞周期和DNA修复机制。EXO1表达增加与更高的WHO分级、IDH野生型、1p/19q非共缺失以及不良预后相关。已经开发了一个将EXO1与临床参数相结合的列线图,以帮助预测患者每隔1年的总生存概率。校准图显示列线图的有效性是准确的(c指数=0.850)。免疫组织化学评估显示,与相邻非肿瘤组织相比,60例胶质瘤组织中EXO1表达水平显著升高。

结论

总之,我们的结果表明胶质瘤中EXO1表达水平显著升高,这与临床病理特征和不良预后密切相关。此外,EXO1成为胶质瘤一个有前景的候选生物标志物和潜在治疗靶点,可能在介导这种恶性肿瘤内的免疫浸润中起关键作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/2e08299d4153/tcr-14-05-2690-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/f520dd91a11d/tcr-14-05-2690-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/318e610c34cd/tcr-14-05-2690-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/345129d5f698/tcr-14-05-2690-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/a116646173ea/tcr-14-05-2690-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/d1e45cb3cd7e/tcr-14-05-2690-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/c674701d93d6/tcr-14-05-2690-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/2e08299d4153/tcr-14-05-2690-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/f520dd91a11d/tcr-14-05-2690-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/318e610c34cd/tcr-14-05-2690-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/345129d5f698/tcr-14-05-2690-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/a116646173ea/tcr-14-05-2690-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/d1e45cb3cd7e/tcr-14-05-2690-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/c674701d93d6/tcr-14-05-2690-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f39/12169988/2e08299d4153/tcr-14-05-2690-f7.jpg

相似文献

1
Construction and validation of a prognostic model for glioma: an analysis based on mismatch repair-related genes and their correlation with clinicopathological features.胶质瘤预后模型的构建与验证:基于错配修复相关基因及其与临床病理特征相关性的分析
Transl Cancer Res. 2025 May 30;14(5):2690-2706. doi: 10.21037/tcr-24-2045. Epub 2025 May 9.
2
Development and validation of a Log odds of negative lymph nodes/T stage ratio-based prognostic model for gastric cancer.基于阴性淋巴结/肿瘤分期比值的胃癌对数优势预后模型的开发与验证
Front Oncol. 2025 Jun 3;15:1554270. doi: 10.3389/fonc.2025.1554270. eCollection 2025.
3
Comprehensive pan-cancer analysis reveals NTN1 as an immune infiltrate risk factor and its potential prognostic value in SKCM.全面的泛癌分析揭示NTN1作为一种免疫浸润风险因素及其在皮肤黑色素瘤中的潜在预后价值。
Sci Rep. 2025 Jan 25;15(1):3223. doi: 10.1038/s41598-025-85444-x.
4
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.基于分子特征的腹膜后脂肪肉瘤分类:一项前瞻性队列研究。
Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887.
5
Interventions for central serous chorioretinopathy: a network meta-analysis.中心性浆液性脉络膜视网膜病变的干预措施:一项网状Meta分析
Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3.
6
Identification of a novel prognostic gene signature in pleural mesothelioma: a study based on The Cancer Genome Atlas database and experimental validation.胸膜间皮瘤中一种新型预后基因特征的鉴定:基于癌症基因组图谱数据库的研究及实验验证
Transl Cancer Res. 2025 May 30;14(5):2981-2998. doi: 10.21037/tcr-2024-2531. Epub 2025 May 27.
7
Prognostic role of tumor microenvironment and immune- and autophagy-related genes in colorectal adenocarcinoma.肿瘤微环境以及免疫和自噬相关基因在结直肠癌中的预后作用
Transl Cancer Res. 2025 May 30;14(5):2835-2857. doi: 10.21037/tcr-24-1708. Epub 2025 May 27.
8
Community views on mass drug administration for soil-transmitted helminths: a qualitative evidence synthesis.社区对土壤传播蠕虫群体药物给药的看法:定性证据综合分析
Cochrane Database Syst Rev. 2025 Jun 20;6:CD015794. doi: 10.1002/14651858.CD015794.pub2.
9
Prognostic factors for return to work in breast cancer survivors.乳腺癌幸存者恢复工作的预后因素。
Cochrane Database Syst Rev. 2025 May 7;5(5):CD015124. doi: 10.1002/14651858.CD015124.pub2.
10
[Ferroptosis-related long non-coding RNA to predict the clinical outcome of non-small cell lung cancer after radiotherapy].[铁死亡相关长链非编码RNA预测非小细胞肺癌放疗后的临床结局]
Beijing Da Xue Xue Bao Yi Xue Ban. 2025 Jun 18;57(3):569-577. doi: 10.19723/j.issn.1671-167X.2025.03.022.

本文引用的文献

1
Establishment and validation of a prognostic prediction model for glioma based on key genes and clinical factors.基于关键基因和临床因素的胶质瘤预后预测模型的建立与验证
Transl Cancer Res. 2025 Jan 31;14(1):240-253. doi: 10.21037/tcr-24-1035. Epub 2025 Jan 20.
2
Prognostic value of CTF1 in glioma and its role in the tumor microenvironment.CTF1在胶质瘤中的预后价值及其在肿瘤微环境中的作用。
Transl Cancer Res. 2024 Dec 31;13(12):6862-6879. doi: 10.21037/tcr-24-1258. Epub 2024 Dec 27.
3
Novel cuprotosis-related gene signature: a prognostic indicator and regulator of the glioma immune microenvironment.
新型铜死亡相关基因特征:一种胶质瘤免疫微环境的预后指标和调节因子。
Transl Cancer Res. 2024 Nov 30;13(11):6282-6297. doi: 10.21037/tcr-24-1860. Epub 2024 Nov 27.
4
Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations.小胶质细胞和单核细胞来源的巨噬细胞推动小儿高级别脑胶质瘤的进展,并通过组蛋白突变在转录水平上被塑造。
Immunity. 2024 Nov 12;57(11):2669-2687.e6. doi: 10.1016/j.immuni.2024.09.007. Epub 2024 Oct 11.
5
Targeted delivery of napabucasin with radiotherapy improves outcomes in diffuse midline glioma.放疗联合靶向递送纳布卡塞可改善弥漫性中线胶质瘤的治疗效果。
Neuro Oncol. 2025 Mar 7;27(3):795-810. doi: 10.1093/neuonc/noae215.
6
Schizophyllum commune fruiting body polysaccharides inhibit glioma by mediating ARHI regulation of PI3K/AKT signalling pathway.糙皮侧耳子实体多糖通过调控 ARHI 抑制 PI3K/AKT 信号通路抑制神经胶质瘤。
Int J Biol Macromol. 2024 Nov;279(Pt 3):135326. doi: 10.1016/j.ijbiomac.2024.135326. Epub 2024 Sep 3.
7
Glioma oncogenesis in the Constitutional mismatch repair deficiency (CMMRD) syndrome.先天性错配修复缺陷(CMMRD)综合征中的胶质瘤发生
Neurooncol Adv. 2024 Jul 11;6(1):vdae120. doi: 10.1093/noajnl/vdae120. eCollection 2024 Jan-Dec.
8
Immunotherapeutic advances in glioma management: The rise of vaccine-based approaches.免疫治疗在神经胶质瘤治疗管理中的进展:基于疫苗的方法的兴起。
CNS Neurosci Ther. 2024 Sep;30(9):e70013. doi: 10.1111/cns.70013.
9
Microbiota and glioma: a new perspective from association to clinical translation.微生物群与神经胶质瘤:从关联到临床转化的新视角。
Gut Microbes. 2024 Jan-Dec;16(1):2394166. doi: 10.1080/19490976.2024.2394166. Epub 2024 Aug 26.
10
Epigenetic clocks and gliomas: unveiling the molecular interactions between aging and tumor development.表观遗传时钟与神经胶质瘤:揭示衰老与肿瘤发生之间的分子相互作用
Front Mol Biosci. 2024 Jul 26;11:1446428. doi: 10.3389/fmolb.2024.1446428. eCollection 2024.